Skip to search formSkip to main contentSkip to account menu

yttrium Y 90 monoclonal antibody M195

Known as: Y 90 MoAb M195, Y90 MOAB M195, Y 90 Monoclonal Antibody M195 
A radioimmunoconjugate of humanized M195 monoclonal antibody (MoAb) conjugated with isotope yttrium 90. MoAb M195 is reactive with the cell surface… 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

monoclonal antibody M195

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Phase I clinical trial of the anti-CD33 immunotoxin HuM195/rgel in patients (pts) with advanced myeloid malignancies.
6549 Background: HuM195 is a humanized version of the mouse M195 anti CD-33 monoclonal antibody. CD33 is heavily expressed on the… 
Review
2003
Review
2003
Coupling of nuclear wavepacket motion and charge separation in bacterial reaction centers
Review
2001
Review
2001
Antibody therapy for residual disease in acute myelogenous leukemia.
Review
1998
Review
1998
Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome.
Disease recurrence following successful bone marrow transplantation remains a major impediment in the management of patients with… 
1994
1994
Epitope analysis of human IL-6 receptor gp80 molecule with monoclonal antibodies.
Gp80 human IL-6R was studied using 7 murine mAb (M37, M91, M113, M139, M164, M182 and M195) obtained after fusion of splenocytes… 
1994
1994
IL-6-induced changes in synthesis of alpha 1-acid glycoprotein in human hepatoma Hep3B cells are distinctively regulated by monoclonal antibodies directed against different epitopes of IL-6 receptor…
The synthesis of the human acute-phase alpha 1-acid glycoprotein (AGP) is primarily controlled by IL-6 and IL-1 in liver cells… 
1993
1993
Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia.
Individual patient response to radioimmunotherapy is influenced by each patient's tumor burden, antibody clearance kinetics and… 
1993
1993
Anti-CD33 monoclonal antibody M195 for the therapy of myeloid leukemia.
Leukemia is well suited for monoclonal antibody therapy due to the accessible, differentiation antigens that characterize stages… 
Review
1993
Review
1993
Treatment of leukemia with radiolabeled monoclonal antibodies.
In contrast to radioimmunotherapy of solid disease, wherein the primary obstacle to success is access of radiolabeled antibody to… 
1992
1992
Spectroscopic and redox properties of sym1 and (M)F195H: Rhodobacter capsulatus reaction center symmetry mutants which affect the initial electron donor.
The redox properties, absorption, electroabsorption, CD, EPR, and P+QA- recombination kinetics have been measured for the special… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)